Valneva SE VLA.PA PAR · Healthcare · France
2.35 € -3.96% -0.10 €
Summary
14 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Revenue fell by 22% a year over the last 3 years.
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 9.6% a year over 5 years. Over the last 3 years it fell by 22% a year. For the next fiscal year analysts expect revenue to fall by 13%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of 157.7M €.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detail